'In Vitro human skin testing; safety, allergy and contact sensitivity'

体外人体皮肤测试；

• 批准号: 720110
• 金额: $ 6.84万
• 依托单位: ALCYOMICS LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Development of Prototype
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=720110
• 关键词: Vitro; human; skin; testing; safety

This project proposal builds on the research conducted under a One North East Grant forResearch and Development awarded to Alcyomics in May 2010. Alcyomics research in 2010developed a unique assay (Skimune™) for allergy and contact sensitivity testing with two UKPatents pending (No GB No1020004.6;GB1115537.1). We now need to further validate theassay by comparing our results with current technologies, including an animal model system(LLNA) and to convert our UK patent into an international patent s. We will also aim tofurther validate the assay as a screening test using inflammatory cytokine measurements andT cell proliferation responses for up to 30 compounds which we will be able to correlate withthe skin explant assay and therefore potency. This is a novel aspect to the assay and deliverskey information about the safety of the compounds. In addition in collaboration with theNIBSC develop the assay further for use in predicting adverse reactions to therapeuticmonoclonal antibodies. Professor Ian Kimber, expert in skin sensitisation and toxicology, willalso act as advisor/consultant to the project.Pilot studies have proved positive and we nowrequire funds to develop and commercialise the assay to market.

该项目提案建立在2010年5月授予Alcyomics的One North East研究与发展赠款下进行的研究基础上。Alcyomics研究在2010年开发了一种独特的检测方法（Skimune™），用于过敏和接触敏感性测试，两项英国专利正在申请中（GB No1020004.6; GB 1115537.1）。我们现在需要通过将我们的结果与当前技术（包括动物模型系统（LLNA））进行比较来进一步验证该检测方法，并将我们的英国专利转化为国际专利。我们还将进一步验证该试验作为一种筛选试验，使用炎症细胞因子测量和T细胞增殖反应，多达30种化合物，我们将能够与皮肤外植体试验和效力相关。这是一个新的方面的分析和deliverskey信息的安全性的化合物。此外，与NIBSC合作，进一步开发用于预测治疗性单克隆抗体不良反应的检测方法。皮肤致敏和毒理学专家Ian Kimber教授也将担任该项目的顾问。初步研究证明是积极的，我们现在需要资金来开发和商业化该检测市场。